Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis
Jianbo Zhou, Xingyao Tang, Min Han, et al.
Metabolism (2020) Vol. 109, pp. 154265-154265
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Metformin: Is it a drug for all reasons and diseases?
Chris R. Triggle, Ibrahim Mohammed, Khalifa Bshesh, et al.
Metabolism (2022) Vol. 133, pp. 155223-155223
Open Access | Times Cited: 182
Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms
Sheng Chen, Donghao Gan, Sixiong Lin, et al.
Theranostics (2022) Vol. 12, Iss. 6, pp. 2722-2740
Open Access | Times Cited: 110
Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Maria Rosaria Rizzo, Irene Di Meo, Rita Polito, et al.
Pharmacological Research (2022) Vol. 176, pp. 106062-106062
Open Access | Times Cited: 101
Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
Ameya Kulkarni, Sandra Aleksić, David M. Berger, et al.
Aging Cell (2022) Vol. 21, Iss. 4
Open Access | Times Cited: 71
Newer glucose‐lowering drugs and risk of dementia: A systematic review and meta‐analysis of observational studies
Huilin Tang, Hui Shao, C. Elizabeth Shaaban, et al.
Journal of the American Geriatrics Society (2023) Vol. 71, Iss. 7, pp. 2096-2106
Closed Access | Times Cited: 53
Dementia Prevention and Treatment
David B. Reuben, Sarah Kremen, Donovan T. Maust
JAMA Internal Medicine (2024) Vol. 184, Iss. 5, pp. 563-563
Open Access | Times Cited: 37
Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis
Y J Youn, Seung Yeon Kim, Hyun‐Jeong Jeong, et al.
Frontiers in Neuroendocrinology (2024) Vol. 73, pp. 101131-101131
Open Access | Times Cited: 20
Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline
Antonio Lardaro, L. Quarta, Stefania Pagnotta, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1750-1750
Open Access | Times Cited: 15
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
Jonathan V Mui, Jiandong Zhou, Sharen Lee, et al.
Frontiers in Cardiovascular Medicine (2021) Vol. 8
Open Access | Times Cited: 71
Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline
Karis Little, María Llorián‐Salvador, Sarah Scullion, et al.
Trends in Endocrinology and Metabolism (2021) Vol. 33, Iss. 1, pp. 50-71
Closed Access | Times Cited: 69
Association between Type 2 Diabetes Mellitus and Brain Atrophy: A Meta-Analysis
Tianqi Zhang, Marnie Shaw, Nicolas Cherbuin
Diabetes & Metabolism Journal (2022) Vol. 46, Iss. 5, pp. 781-802
Open Access | Times Cited: 47
Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study
Yang Du, Yajuan Zhu, Yixin Zhou, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 40
Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders
Nuojin Li, Tian Zhou, Erkang Fei
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8281-8281
Open Access | Times Cited: 39
Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
Yixuan Wang, Hao Hu, Xinyu Liu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 35
Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta‐analysis
Sai Tian, Jiaxuan Jiang, Jin Wang, et al.
Diabetes/Metabolism Research and Reviews (2023) Vol. 39, Iss. 7
Closed Access | Times Cited: 30
Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis
Alvin Kuate Defo, Veselko Bakula, Alessandro Pisaturo, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 2, pp. 441-462
Open Access | Times Cited: 29
Vascular cognitive impairment and dementia: Mechanisms, treatment, and future directions
Vincent Mok, Cai Yuan, Hugh S Markus
International Journal of Stroke (2024) Vol. 19, Iss. 8, pp. 838-856
Closed Access | Times Cited: 9
The Anti-Aging Mechanism of Metformin: From Molecular Insights to Clinical Applications
Ting Zhang, Zhou Li-jun, Meagan J. Makarczyk, et al.
Molecules (2025) Vol. 30, Iss. 4, pp. 816-816
Open Access | Times Cited: 1
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias
Huilin Tang, William T. Donahoo, Steven T. DeKosky, et al.
JAMA Neurology (2025)
Closed Access | Times Cited: 1
Targeting Insulin Resistance to Treat Cognitive Dysfunction
Anit Tyagi, Subbiah Pugazhenthi
Molecular Neurobiology (2021) Vol. 58, Iss. 6, pp. 2672-2691
Open Access | Times Cited: 43
Reassessment of Pioglitazone for Alzheimer’s Disease
Ann M. Saunders, Daniel K. Burns, William Gottschalk
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 43
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
Yidan Chen, Xingfei Lv, Sang Lin, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 34
Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia
Wiebe M. C. Top, Adriaan Kooy, Coen D.A. Stehouwer
Pharmaceuticals (2022) Vol. 15, Iss. 3, pp. 312-312
Open Access | Times Cited: 32
Association Between Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Cognitive Function in a Longitudinal Study of Patients with Type 2 Diabetes
Serena Low, Kiat Sern Goh, Tze Pin Ng, et al.
Journal of Alzheimer s Disease (2022) Vol. 87, Iss. 2, pp. 635-642
Closed Access | Times Cited: 32
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Federica Ferrari, Antonio Moretti, R. F. Villa
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108277-108277
Closed Access | Times Cited: 32
Page 1 - Next Page

Scroll to top